Uihlein Richard E 4

What Happened Richard E. Uihlein, reported as a 10% owner of Galectin Therapeutics, received two awards on January 16, 2026: 13,158 restricted shares issued in lieu of a $40,000 cash retainer/meeting fees (priced at $3.04 each), and an award of 60,000 stock options (recorded as a derivative award with $0 cash price). These were reported on a Form 4 filed January 21, 2026.

Key Details

• Transaction date: January 16, 2026; Form 4 filed January 21, 2026 (filed 5 calendar days after the transaction; likely late since Form 4 is generally due within 2 business days).
• Awards: 13,158 restricted shares @ $3.04 = $40,000; 60,000 stock options (derivative award, $0 cash outlay reported).
• Vesting/restrictions: Restricted shares lapse 25% at the end of each calendar quarter in 2026 (fully vested by year end); the 60,000 options vest 100% on December 31, 2026.
• Shares owned after the transaction: Not disclosed in the provided filing.
• Beneficial ownership note: Uihlein is president/director of the Ed Uihlein Family Foundation and has voting/dispositive power over the shares held by the foundation; he has no pecuniary interest but is treated as beneficial owner for Section 13(d) purposes.

Context This filing records awards (not open-market purchases or sales). The 13,158 shares were issued in lieu of cash compensation and carry time-based restrictions; the 60,000-share derivative award are options that vest at year-end 2026. As a 10% owner acting through a not-for-profit foundation, these transactions reflect institutional/fiduciary holdings rather than routine executive buy/sell activity.